Cancer drugs help Johnson & Johnson raise sales outlook
By Manas Mishra and Manojna Maddipatla - Jul 17th, 08:41
Johnson & Johnson raised its full-year sales forecast as demand for its cancer drugs Darzalex and Imbruvica helped it exceed estimates for second-quarter profit on Tuesday.
J&J’s pharmaceuticals unit has cushioned impact of slow growth in its medical device and consumer health units, largely due to its cancer drugs, even as some of its older drugs face competition.
The company raised its 2019 forecast for operational sales, which excludes the impact of currency fluctuations, to $82.4bn-$83.2bn, from a prior $82bn-$82.8bn.
“We expect questions on the maintained earnings-per-share guidance but we point to the continued-to-be-improving strength across its franchises despite pharma headwinds,” said BMO Capital Markets analyst Joanne Wuensch.
J&J reported a 41.8% fall in litigation expense to $409m in the quarter. But the company recorded litigation expense of $832m in six months, compared with $703m.
J&J faces lawsuits that allege drugmakers, including the company, overstated the benefits of opioids while downplaying their addictive risks when marketing their pain treatments.
The company also disclosed in its annual report in February that it had received subpoenas from the US justice department and Securities and Exchange Commission related to baby-powder litigation but did not give more details.
J&J repeatedly has said its talcum products are safe and that decades of studies have shown them to be asbestos-free and that they do not cause cancer.
In the quarter, pharmaceutical sales rose 1.7% to $10.53bn, above analysts’ estimates of $10.27bn, according to three analysts polled by Refinitiv.
Sales of prostate-cancer treatment Zytiga and blood thinner Xarelto and J&J’s blockbuster arthritis drug Remicade all fell, hurt by competition.
Darzalex and Imbruvica recorded sales of $774m and $831m respectively and came in ahead of estimates.
The diversified health-care company, the first major US drugmaker to report second-quarter results, said net earnings rose to $5.61bn, or $2.08 a share, from $3.95bn, or $1.45 a share, a year earlier.
Excluding items, the company earned $2.58 a share, beating analysts’ expectations for $2.46 a share, according to Ibes data from Refinitiv.
Sales fell 1.3% to $20.56bn as growth in international markets helped counter falling sales in the US. Analysts were expecting sales of $20.29bn.
Shares of the company were marginally up at $135.6 in trading before the opening bell.
Truworths profit at nine-year low as profit plunges over 70%
16/08/2019 - 11:52
Shares in Truworths slumped to a nine-year low on Friday morning after the fashion retailer reported a 74% slide in profits amid difficult trading environments in SA and the UK.
UnionPay cards - the largest card scheme in the world - now accepted at all Pick n Pay stores across SA
16/08/2019 - 11:11
UnionPay International (UPI) has announced significant progress in the South African retail payments market through their co-operation with Pick n Pay and Absa Bank. Through a tripartite co-operation agreement, Pick n Pay, a major food, clothing, and general merchandise retailer, is now enabled to accept UnionPay cards at all of its till points across its approximately 1,800 stores countrywide.
Pernod Ricard SA to centralise operations with Johannesburg move
16/08/2019 - 10:27
In a move set to enhance cohesion, collaboration and efficiencies, Pernod Ricard South Africa (PRSA), a co-leader of wine and spirits worldwide will officially relocate its Cape Town offices to Woodmead, Johannesburg by 31st December this year.
Why equipment finance makes sense for your SME
15/08/2019 - 15:26
Every business, be it in retail, agriculture, and even tech, simply cannot operate without the necessary equipment to run their operations. Equipment can be costly, and that is why equipment finance for small businesses appeals to most small-medium business owners.
AI to change contact centre customer experience
15/08/2019 - 10:05
With investments in artificial intelligence (AI) related technologies expected to triple by 2020, local companies are looking at ways to integrate it into all aspects of their business. It is especially in the contact centre industry where it can be used to greatly enhance the customer experience (CX). And yet, AI is not such a new thing.